Rotavirus vaccination in the neonatal intensive care units: where are we? A rapid review of recent evidence.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
19
12
2019
medline:
28
10
2020
entrez:
19
12
2019
Statut:
ppublish
Résumé
Rotavirus is a leading cause of viral acute gastroenteritis in infants. Neonates hospitalized in neonatal intensive care units (NICUs) are at risk of rotavirus infections with severe outcomes. The administration of rotavirus vaccines is only recommended, in the United States and Canada, upon discharge from the NICU despite rotavirus vaccines being proven well tolerated and effective in these populations, because of risks of live-attenuated vaccine administration in immunocompromised patients and theoretical risks of rotavirus vaccine strains shedding and transmission.We aimed to summarize recent evidence regarding rotavirus vaccine administration in the NICU setting and safety of rotavirus vaccines in preterm infants. We conducted a rapid review of the literature from the past 10 years, searching Medline and Embase, including all study types except reviews, reporting on rotavirus vaccines 1 and 5; NICU setting; shedding or transmission; safety in preterm. One reviewer performed data extraction and quality assessment. Thirty-one articles were analyzed. Vaccine-derived virus shedding following rotavirus vaccines existed for nearly all infants, mostly during the first week after dose 1, but with rare transmission only described in the household setting. No case of transmission in the NICU was reported. Adverse events were mild to moderate, occurring in 10-60% of vaccinated infants. Extreme premature infants or those with underlying gastrointestinal failure requiring surgery presented with more severe adverse events. Recommendations regarding rotavirus vaccine administration in the NICU should be reassessed in light of the relative safety and absence of transmission of rotavirus vaccine strains in the NICU.
Identifiants
pubmed: 31851055
doi: 10.1097/MOP.0000000000000869
pii: 00008480-202002000-00023
doi:
Substances chimiques
Rotavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-191Références
Senecal M, Brisson M, Lebel MH, et al. Measuring the impact of rotavirus acute gastroenteritis episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol 2008; 19:397–404.
Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008; 122:1235–1243.
Troeger C, Khalil IA, Rao PC, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr 2018; 172:958–965.
Cortese MM, Parashar UD. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58:1–25.
Committee on Infectious D, American Academy of P,. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009; 123:1412–1420.
(NACI) NACoI. Updated statement on the use of rotavirus vaccines: an advisory committee statement (ACS) National Advisory Committee on Immunization (NACI). Can Commun Dis Rep 2010; 36:1–37.
Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23–33.
Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11–22.
Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757–1763.
Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181–1189.
Leshem E, Tate JE, Steiner CA, et al. National estimates of reductions in acute gastroenteritis-related hospitalizations and associated costs in US children after implementation of rotavirus vaccines. J Pediatr Infect Dis Soc 2018; 7:257–260.
Shah MP, Dahl RM, Parashar UD, Lopman BA. Annual changes in rotavirus hospitalization rates before and after rotavirus vaccine implementation in the United States. PLoS One 2018; 13:e0191429.
Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and healthcare utilization for diarrhea in the United States. Pediatrics 2014; 134:15–23.
Doll MK, Quach C, Buckeridge DL. Evaluation of the impact of a rotavirus vaccine program on pediatric acute gastroenteritis hospitalizations: estimating the overall effect attributable to the program as a whole and as a per-unit change in rotavirus vaccine coverage. Am J Epidemiol 2018; 187:2029–2037.
Dahl RM, Curns AT, Tate JE, Parashar UD. Effect of rotavirus vaccination on acute diarrheal hospitalizations among low and very low birth weight US infants. Pediatr Infect Dis J 2018; 37:817–822.
Gosselin V, Genereux M, Gagneur A, Petit G. Effectiveness of rotavirus vaccine in preventing severe gastroenteritis in young children according to socioeconomic status. Hum Vaccin Immunother 2016; 12:2572–2579.
Payne DC, Englund JA, Weinberg GA, et al. Association of rotavirus vaccination with inpatient and emergency department visits among children seeking care for acute gastroenteritis. JAMA Netw Open 2019; 2:e1912242.
Tai IC, Huang YC, Lien RI, et al. Clinical manifestations of a cluster of rotavirus infection in young infants hospitalized in neonatal care units. J Microbiol Immunol Infect 2012; 45:15–21.
Newman RD, Grupp-Phelan J, Shay DK, Davis RL. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999; 103:E3.
Dennehy PH, Cortese MM, Begue RE, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J 2006; 25:1123–1131.
Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31:487–493.
Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007; 26:1099–1104.
Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005; 192: (Suppl 1): S6–S16.
Aliabadi N, Wikswo ME, Tate JE, et al. Factors associated with rotavirus vaccine coverage. Pediatrics 2019; 143.
Hofstetter AM, Jacobson EN, deHart MP, et al. Early childhood vaccination status of preterm infants. Pediatrics 2019; 144:e20183520.
Baker JM, Dahl RM, Cubilo J, et al. Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data. BMC Infect Dis 2019; 19:186.
Baker JM, Tate JE, Steiner CA, et al. Longer-term direct and indirect effects of infant rotavirus vaccination across all ages in the United States in 2000–2013: analysis of a large hospital discharge data set. Clin Infect Dis 2019; 68:976–983.
Tricco AC, Straus SE. World Health Organization, Rapid reviews to strengthen health policy and systems: a practical guide. Geneva: 2017.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
Smith CK, McNeal MM, Meyer NR, et al. Rotavirus shedding in premature infants following first immunization. Vaccine 2011; 29:8141–8146.
Vesikari T, Karvonen A, Bouckenooghe A, et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine 2011; 29:2079–2084.
Miura H, Kawamura Y, Sugata K, et al. Rotavirus vaccine strain transmission by vaccinated infants in the foster home. J Med Virol 2017; 89:79–84.
Hsieh Y-C, Wu F-T, Hsiung CA, et al. Comparison of virus shedding after lived attenuated and pentavalent reassortant rotavirus vaccine. Vaccine 2014; 32:1199–1204.
Boom JA, Sahni LC, Payne DC, et al. Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis 2012; 206:1275–1279.
Donato CM, Ch’ng LS, Boniface KF, et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect Dis 2012; 206:377–383.
Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010; 125:e438–e441.
Hemming M, Vesikari T. Vaccine-derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J 2012; 31:992–994.
Hemming M, Vesikari T. Detection of rotateq vaccine-derived, double-reassortant rotavirus in a 7-year-old child with acute gastroenteritis. Pediatr Infect Dis J 2014; 33:655–656.
Yen C, Jakob K, Esona MD, et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine 2011; 29:4151–4155.
Rivera L, Pena LM, Stainier I, et al. Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins. Vaccine 2011; 29:9508–9513.
Sakon N, Miyamoto R, Komano J. An infant with acute gastroenteritis caused by a secondary infection with a Rotarix-derived strain. Eur J Pediatr 2017; 176:1275–1278.
Bennett A, Pollock L, Jere KC, et al. Infrequent transmission of monovalent human rotavirus vaccine virus to household contacts of vaccinated infants in Malawi. J Infect Dis 2019; 219:1730–1734.
Mijatovic-Rustempasic S, Immergluck LC, Parker TC, et al. Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix. Hum Vacc Immunother 2017; 13:928–935.
Markkula J, Hemming M, Vesikari T. Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq vaccination. Pediatr Infect Dis J 2015; 34:296–298.
Ye S, Whiley DM, Ware RS, et al. Multivalent rotavirus vaccine and wild-type rotavirus strain shedding in Australian infants: a birth cohort study. Clin Infect Dis 2018; 66:1411–1418.
Ye S, Whiley DM, Ware RS, et al. Detection of viruses in weekly stool specimens collected during the first 2 years of life: a pilot study of five healthy Australian infants in the rotavirus vaccine era. J Med Virol 2017; 89:917–921.
Bautista-Marquez A, Velasquez DE, Esparza-Aguilar M, et al. Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix immunization in Mexican infants. Vaccine 2016; 34:5284–5289.
Hiramatsu H, Suzuki R, Nagatani A, et al. Rotavirus vaccination can be performed without viral dissemination in the neonatal intensive care unit. J Infect Dis 2018; 217:589–596.
Hofstetter AM, Lacombe K, Klein EJ, et al. Risk of rotavirus nosocomial spread after inpatient pentavalent rotavirus vaccination. Pediatrics 2018; 141:e20171110.
Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics 2014; 133:e1555–e1560.
Jaques SC, Ogley L, Duffy D, Kennea N. Rotavirus immunisation in NICU: A 1-year experience in a UK tertiary neonatal surgical unit postvaccine introduction. Arch Dis Childhood: Fetal Neonatal Ed 2015; 100:F186–F187.
Javid PJ, Sanchez SE, Jacob S, et al. The safety and immunogenicity of rotavirus vaccination in infants with intestinal failure. J Pediatr Infect Dis Soc 2014; 3:57–65.
Fang AY, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J Paediatr Child Health 2012; 48:512–516.
Thrall S, Doll MK, Nhan C, et al. Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. Vaccine 2015; 33:5095–5102.
Kilich E, Anthony M. Rotavirus vaccination in preterm infants: a neonatal guidance chart to aid timely immunisation. Arch Dis Childhood: Fetal Neonatal Ed 2015; 100:F465.
Stumpf KA, Thompson T, Sanchez PJ. Rotavirus vaccination of very low birth weight infants at discharge from the NICU. Pediatrics 2013; 132:e662–e665.
Roue JM, Nowak E, Le Gal G, et al. Impact of rotavirus vaccine on premature infants. Clin Vacc Immunol 2014; 21:1404–1409.
McGrath EJ, Thomas R, Duggan C, Asmar BI. Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease. J Pediatr Gastroenterol Nutr 2014; 59:44–48.
Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31:487–493.
Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum Vacc Immunother 2013; 9:1626–1633.
Crawford SE, Ramani S, Tate JE, et al. Rotavirus infection. Nat Rev Dis Primers 2017; 3:17083.
Prelog M, Gorth P, Zwazl I, et al. Universal mass vaccination against rotavirus: indirect effects on rotavirus infections in neonates and unvaccinated young infants not eligible for vaccination. J Infect Dis 2016; 214:546–555.
Pollard SL, Malpica-Llanos T, Friberg IK, et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine 2015; 33:3795–3800.
Mast TC, Wang FT, Su S, Seeger JD. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. Pediatr Infect Dis J 2015; 34:615–620.
Phillips G, Lopman B, Tam CC, et al. Diagnosing rotavirus A associated IID: using ELISA to identify a cut-off for real time RT-PCR. J Clin Virol 2009; 44:242–245.
Ramani S, Sankaran P, Arumugam R, et al. Comparison of viral load and duration of virus shedding in symptomatic and asymptomatic neonatal rotavirus infections. J Med Virol 2010; 82:1803–1807.
Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 2000; 19:S103–105.
Zerr DM, Allpress AL, Heath J, et al. Decreasing hospital-associated rotavirus infection: a multidisciplinary hand hygiene campaign in a children's hospital. Pediatr Infect Dis J 2005; 24:397–403.
Verhagen P, Moore D, Manges A, Quach C. Nosocomial rotavirus gastroenteritis in a Canadian paediatric hospital: incidence, disease burden and patients affected. J Hosp Infect 2011; 79:59–63.
Sharma R, Garrison RD, Tepas JJ 3rd, et al. Rotavirus-associated necrotizing enterocolitis: an insight into a potentially preventable disease? J Pediatr Surg 2004; 39:453–457.
Bagci S, Eis-Hubinger AM, Yassin AF, et al. Clinical characteristics of viral intestinal infection in preterm and term neonates. Eur J Clin Microbiol Infect Dis 2010; 29:1079–1084.
Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314–319.